Directing Reversible Cell-Cell Interactions with Evolved Fibronectin Domains

摘要

Targeted molecular recognition continues to be a cornerstone of contemporary therapeutics and diagnostics.Though antibodies are commonly employed,as targeting scaffolds,their large size,long plasma half life,and lack of facile bioconjugation make antibody-based ligands less than ideal for many basic and clinical applications.As the repertoire of clinically relevant biomarkers continues to grow,there is an increasing need to develop new agents capable of selectively identifying and targeting these markers.